Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.
de Bono, JS
MetadataShow full item record
We aimed to understand the relative contributions of inhibiting MEK and AKT on cell growth to guide combinations of these agents.A panel of 20 cell lines was exposed to either the MEK inhibitor, PD0325901, or AKT inhibitor, AKT 1/2 inhibitor. p-ERK and p-S6 ELISAs were used to define degrees of MEK and AKT inhibition, respectively. Growth inhibition to different degrees of MEK and AKT inhibition, either singly or in combination using 96-h sulphorhodamine assays was then studied.A significantly greater growth inhibition was seen in BRAF(M) and PIK3CA(M) cells upon maximal MEK (P = 0.004) and AKT inhibition (P = 0.038), respectively. KRAS(M) and BRAF/PIK3CA/KRAS(WT) cells were not significantly more likely to be sensitive to MEK or AKT inhibition. Significant incremental growth inhibition of the combination of MEK + AKT over either MEK or AKT inhibition alone was seen when MEK + AKT was inhibited maximally and not when sub-maximal inhibition of both MEK + AKT was used (11/20 cell lines versus 1/20 cell lines; P = 0.0012).KRAS(M) cells are likely to benefit from combinations of MEK and AKT inhibitors. Sub-maximally inhibiting both MEK and AKT within a combination, in a majority of instances, does not significantly increase growth inhibition compared with maximally inhibiting MEK or AKT alone and alternative phase I trial designs are needed to clinically evaluate such combinations.
Version of record
Tumor Cells, Cultured
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase 1
Protein Kinase Inhibitors
Enzyme-Linked Immunosorbent Assay
Proto-Oncogene Proteins p21(ras)
Proto-Oncogene Proteins c-akt
Medicine (Banerji Drug Evaluation PD Group)
Medicine Drug Development Unit (de Bono)
License start date
Annals of oncology : official journal of the European Society for Medical Oncology, 2015, 26 (7), pp. 1504 - 1510